World Health Organisation., World Health Report 2001 Mental health : New understanding, new hope. Geneva : World Health Organization 2001.
Kessler RC, McGonagle KA, Zhao s, et al., Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry, 1994, 51, 8-19.
Pitchot W, Dierick M, D'Haenen H., Troubles affectifs. In Dierick M, Ansseau M, D'Haenen H, Peuskens J, Linkowski P (Eds), Manuel de Psychopharmacologie. Gent Academia Press, 2003, 169-229.
Keller M., Remission versus response : The new gold standard of antidepressant care. J Clin Psychiatry, 2004, 65 (suppl 4), 53-59.
Rush AJ, Trivedi MH, Wisniewski SR et al., Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med, 2006, 354, 1231-1242.
Pitchot W, Scantamburno G., Comment s'adapter à la mauvaise réputation de la dépression ? Rev Med Liège, 2013, 68, 186-189.
Pitchot W, Scantamburlo G, Pinto E., Guérir de la dépression : Une question d'objectif et de détermination. Rev Med Liège, 2010, 65, 370-380.
Bollen J, Constant E, Domken MA, et al., Striving for remission in depression through bette rand broader symptom control. Acta Psychiatrica Belgica, 2006, 106, 121-133.
Ferrier IN., Characterizing the ideal antidepressant therapy to achieve remission. J Clin Psychiatry, 2001, 62 (suppl 26), 10-15.
Saltiel PF, Silvershein DI., Major depressive disorder: Mechanism-based prescribing for personalized medecine. Neuropsychiatr Dis Treat, 2015, 11, 875-888.
Papakostas GI, Nutt DJ, Hallett LA, et al., Resolution of sleepiness and fatigue in major depressive disorder : A comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry, 2006, 60, 1350-1355.
Pitchot W, Scantamburlo G, Souery D., Des antipsychotiques dans la dépression. Rev Med Liège, 2013, 68, 521-526.
Pitchot W, Scantamburlo G, Ansseau M, Souery D., Le trouble bipolaire : Une affection bien complexe ⋯ Rev Med Liège, 2012, 67, 366-373
Souery D, Oswald P, Massat I, et al., Clinical factors associated with treatment resistance in major depressive disorder: Results from a European multicenter study. J Clin Psychiatry, 2007, 68, 1062-1070.
Flint J, Kendler KS., The genetics of major depression. Neuron, 2014, 81, 484-503.
Fabbri C, Porcelli S, Serretti A., From pharmacogenetics to pharmacogenomics : The way toward the personalization of antidepressant treatment. Can J Psychiatry, 2014, 59, 62-75.
Ozomaro U, Wahlestedt C, Nemeroff CB., Personalized medicine in psychiatry : Problems and promises. BMC Med, 2013, 11, 132.
Drago A, De Ronchi D, Serretti A., Pharmacogenetics of antidepressant response. Hum Genomics, 2009, 3, 257-274.
Serretti A, Kato M, de Ronchi D, et al., Meta-Analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry, 2007, 12, 247-257.
Huezo-Diaz P, Uher R, Smith R, et al., Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry, 2009, 195, 30-38.
Pitchot W, Polis M, Belachew S, et al., Dépression etneuroplasticité. Rev Med Liège, 2008, 63, 372-377.
Colle R, Gressier F, Verstuyft C, et al., Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients. J Affect Disord, 2015, 175, 233-240.
